促消退介质消退素E1恢复急性呼吸窘迫综合征肺泡液体清除
该研究在大鼠脂多糖(LPS,14 mg/kg)诱导的ARDS模型中,于造模后6小时静脉注射消退素E1(RvE1,10 μg/kg),3小时后测定肺泡液体清除。RvE1提高生存率(30% vs 70%,P=0.048)、增加肺泡液体清除(13.34% vs 18.73%,P<0.001)、降低肺湿干重比(5.01 vs 4.63,P<0.001)、减轻肺损伤评分(13.38 vs 7.0,P<0.05)及炎症。体外原代II型肺泡上皮细胞中,RvE1上调ENaC与NKA表达,激活PI3K/AKT/SGK1通路;PI3K抑制剂LY294002和SGK1抑制剂GSK650394可阻断上述效应。作者认为RvE1可能通过PI3K/AKT/SGK1通路上调ENaC和NKA促进肺泡液体清除,可能是ARDS的潜在有效药物。
要点
- LPS诱导ARDS大鼠造模后6小时静脉注射RvE1 10 μg/kg,3小时后测肺泡液体清除,生存率30% vs 70%(P=0.048)。
- RvE1使肺泡液体清除率由13.34%升至18.73%(P<0.001),肺湿干重比由5.01降至4.63(P<0.001)。
- RvE1使肺损伤评分由13.38降至7.0(P<0.05),并减轻LPS诱导的肺部炎症。
- 体外原代II型肺泡上皮细胞中,RvE1(250 nM)上调ENaC和NKA,激活PI3K/AKT/SGK1通路。
- LY294002阻断PI3K、GSK650394阻断SGK1后,RvE1的效应被消除。
适用人群与场景
- LPS(14 mg/kg)诱导的急性呼吸窘迫综合征大鼠模型,造模后6小时给药。
- 体外原代II型肺泡上皮细胞,LPS 1 μg/mL刺激,加或不加RvE1 250 nM。
处置流程与药物剂量
- 大鼠LPS(14 mg/kg)诱导后6小时静脉注射RvE1 10 μg/kg,再3小时后测定肺泡液体清除(n=8-9)。
- 体外原代II型肺泡上皮细胞以LPS 1 μg/mL刺激,加或不加RvE1 250 nM处理。
- 以LY294002阻断PI3K、GSK650394阻断SGK1,分别消除RvE1的效应。
研究设计与关键结果
- 研究类型:动物实验(大鼠LPS诱导ARDS模型)及原代II型肺泡上皮细胞体外实验。
- RvE1提高生存率(30% vs 70%,P=0.048)。
- RvE1增加肺泡液体清除(13.34% vs 18.73%,P<0.001)。
- RvE1降低肺湿干重比(5.01 vs 4.63,P<0.001)。
- RvE1减轻肺损伤评分(13.38 vs 7.0,P<0.05)及炎症。
- RvE1在体内和体外上调肺泡ENaC和NKA表达。
- 在LPS刺激的原代II型肺泡上皮细胞中,RvE1显著增加磷酸化AKT、SGK1和磷酸化Nedd4-2表达。
- LY294002阻断PI3K、GSK650394阻断SGK1后,RvE1的效应被消除。
证据类型、等级与局限
- 证据类型:动物实验与体外细胞实验。
- 作者结论:RvE1通过激活PI3K/AKT/SGK1通路上调ENaC和NKA促进肺泡液体清除,提示RvE1可能是ARDS治疗的潜在有效药物。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为RvE1可能通过PI3K/AKT/SGK1通路上调ENaC和NKA促进肺泡液体清除,可能是ARDS治疗的潜在有效药物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by increased permeability of the alveolar-capillary barrier and impaired alveolar fluid clearance. Resolvin E1 (RvE1) is a specialized pro-resolving mediator derived endogenously from omega-3-polyunsaturated fatty acids. RvE1 (10 μg/kg i.v.) was injected to rats 6 h post-lipopolysaccharide (LPS) (14 mg/kg) induction. After another 3 h, alveolar fluid clearance was measured in live rats (n = 8-9). The primary Type II alveolar epithelial cell was isolated and treated by LPS (1 μg/mL) with or without RvE1 (250 nM). The expression of epithelial sodium channel (ENaC), Na+/K+-ATPase (NKA), AKT, serum- and glucocorticoid-induced kinase 1 (SGK1), and Nedd4-2 were detected. RvE1 improved survival rate (30% vs. 70%, P = 0.048), increased the clearance of alveolar fluid (13.34% vs. 18.73%, P < 0.001), reduced lung wet-dry weight ratio (5.01 vs. 4.63, P < 0.001), mitigated lung injury scores (13.38 vs. 7.0, P < 0.05) and inflammation in LPS-induced ARDS in rats. RvE1 upregulated alveolar ENaC and NKA expression in vivo and in vitro. In addition, RvE1 significantly increased the expression of phosphorylated AKT, SGK1, and phosphorylated Nedd4-2 in LPS-stimulated primary alveolar type II cells. The effects of RvE1 were abrogated by blocking phosphatidylinositide3'-kinase (PI3K) and SGK1 with LY294002 and GSK650394, respectively. In summary, RvE1 upregulated ENaC and NKA expression by activating PI3K/AKT/SGK1 pathway to promote alveolar fluid clearance, suggesting that RvE1 may be a potentially effective drug for ARDS treatment.
参考来源
- Luo J, Zhang WY, Li H, et al. Pro-Resolving Mediator Resolvin E1 Restores Alveolar Fluid Clearance in Acute Respiratory Distress Syndrome. Shock. 2022. PMID: 35271545. doi:10.1097/SHK.0000000000001865
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。